/PRNewswire/ Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration.
On January 23, 2024, Heron Therapeutics announced the FDA had approved its sNDA for bupivacaine and meloxicam extended-release solution to expand the indication to include soft tissue and orthopedic surgical procedures, including procedures in which direct exposure to articular cartilage is avoided.
Zynrelef's expanded FDA approval for soft tissue and orthopedic surgeries, offering superior pain management with lower pain scores and opioid consumption.
The FDA has approved Heron Therapeutics Inc’s (NASDAQ:HRTX) supplemental New Drug Application for Zynrelef (bupivacaine and meloxicam) extended-release solution to expand the indication for soft tissue and orthopedic surgical procedures, including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided. Zynrelef was previously approved for foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures in ad
Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.